### **Brilliant Violet 570™ anti-human CD3**

Catalog # / Size: 2102180 / 100 tests

2102175 / 25 tests

Clone: UCHT1

**Isotype:** Mouse IgG1, κ

Reactivity: Human

**Preparation:** The antibody was purified by affinity

chromatography and conjugated with Brilliant Violet 570<sup>™</sup> under optimal conditions. The solution is free of unconjugated Brilliant Violet 570<sup>™</sup> and

unconjugated antibody.


**Formulation:** Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and BSA

(origin USA).

Workshop Number: III 471

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with CD19 APC and CD3 (clone UCHT1) Brilliant Violet 570™ (top) or mouse lgG1, κ Brilliant Violet 570™ isotype control (bottom).

## **Applications:**

**Applications:** Flow Cytometry

Recommended


**Usage:** 

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 570™ excites at 405 nm and emits at 570 nm. The bandpass filter 585/42 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet

manufacturer for support. Brilliant Violet 570™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research



purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

# Application Notes:

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections<sup>4,6,7</sup> and formalin-fixed paraffin-embedded sections<sup>11</sup>, immunoprecipitation1, activation of T cells<sup>2,3,5</sup>, and Western blotting<sup>9</sup>. The LEAF<sup>™</sup> purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 um filtered) is recommended for functional assays (Cat. No. 300414). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 300438) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/microg).

# Application References:

- 1. Salmeron A, et al. 1991. J. Immunol. 147:3047. (IP)
- 2. Graves J, et al. 1991. J. Immunol. 146:2102. (Activ)
- 3. Lafont V, et al. 2000. J. Biol. Chem. 275:19282. (Activ)
- 4. Ryschich E, et al. 2003. Tissue Antigens 62:48. (IHC)
- 5. Thompson AG, et al. 2004. J. Immunol. 173:1671. (Activ)
- 6. Sakkas Ll, et al. 1998. Clin. Diagn. Lab. Immun. 5:430. (IHC)
- 7. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
- 8. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
- 9. Van Dongen JJM, et al. 1988. Blood 71:603. (WB)
- 10. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- 11. Pollard, K. et al. 1987. J. Histochem. Cytochem. 35:1329. (IHC)
- 12. Luckashenak N, et al. 2013. J. Immunol. 190:27. PubMed.

#### **Description:**

CD3 $\epsilon$  is a 20 kD chain of the CD3/T-cell receptor (TCR) complex which is composed of two CD3 $\epsilon$ , one CD3 $\gamma$ , one CD3 $\delta$ , one CD3 $\delta$  (CD247), and a T-cell receptor ( $\alpha/\beta$  or  $\gamma/\delta$ ) heterodimer. It is found on all mature T cells, NKT cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

## Antigen References:

- 1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
- 2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
- 3. Lanier L, et al. 1986. J. Immunol. 137:2501-2507.